Organogenesis wins US OK for first cell-based mucogingival therapy
This article was originally published in Scrip
Executive Summary
The US FDA on 9 March cleared Organogenesis' Gintuit for use as part of a surgical procedure to treat oral mucogingival, soft tissue defects involving the gums and other oral tissue at the juncture with the gingival.